PRMT5 and neuroblastoma: As shown in Fig. 4B, there are highly significant overlaps between DEGs, DSGs, PRMT5 expression versus the MYCN-157 signature, indicating that the genes which showed altered expression following PRMT5 inhibition, together with PRMT5, had significantly higher expression in MNA neuroblastoma and were co-expressed with the MYCN157 prognostic signature in the SEQC neuroblastoma dataset of 498 tumours.